TapImmune (NASDAQ:MRKR) Trading 15% Higher Following Insider Buying Activity

Shares of TapImmune Inc. (NASDAQ:MRKR) traded up 15% during mid-day trading on Friday after an insider bought additional shares in the company. The company traded as high as $5.70 and last traded at $5.52, 897,766 shares traded hands during trading. An increase of 88% from the average session volume of 478,193 shares. The stock had previously closed at $4.80.

Specifically, insider Peter L. Hoang bought 10,000 shares of the stock in a transaction dated Wednesday, August 14th. The shares were purchased at an average price of $4.62 per share, for a total transaction of $46,200.00. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 23.70% of the stock is owned by corporate insiders.

MRKR has been the subject of a number of analyst reports. Zacks Investment Research cut TapImmune from a “buy” rating to a “hold” rating in a report on Wednesday, July 17th. Nomura reaffirmed a “buy” rating and issued a $16.00 price target on shares of TapImmune in a report on Tuesday. Oppenheimer initiated coverage on TapImmune in a report on Wednesday, July 3rd. They issued an “outperform” rating and a $15.00 price target for the company. Janney Montgomery Scott reaffirmed a “buy” rating on shares of TapImmune in a report on Sunday, July 21st. Finally, ValuEngine raised TapImmune from a “hold” rating to a “buy” rating in a report on Thursday, August 1st. One analyst has rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus price target of $10.21.

The company has a fifty day simple moving average of $6.48 and a two-hundred day simple moving average of $5.99. The company has a debt-to-equity ratio of 0.01, a quick ratio of 19.73 and a current ratio of 16.85. The company has a market capitalization of $214.65 million, a price-to-earnings ratio of -3.31 and a beta of 0.22.

TapImmune (NASDAQ:MRKR) last issued its quarterly earnings results on Thursday, August 8th. The company reported ($0.12) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.13) by $0.01. As a group, analysts expect that TapImmune Inc. will post -0.51 EPS for the current year.

An institutional investor recently raised its position in TapImmune stock. Riggs Asset Managment Co. Inc. increased its holdings in shares of TapImmune Inc. (NASDAQ:MRKR) by 68.4% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 45,919 shares of the company’s stock after purchasing an additional 18,650 shares during the period. Riggs Asset Managment Co. Inc. owned 0.10% of TapImmune worth $303,000 as of its most recent filing with the Securities and Exchange Commission. Institutional investors and hedge funds own 33.63% of the company’s stock.

TapImmune Company Profile (NASDAQ:MRKR)

Marker Therapeutics, Inc, a clinical-stage immuno-oncology company, develops and commercializes novel cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. Its MultiTAA T cell technology is based on the tumor-specific T cells that recognize tumor associated antigens and kill tumor cells expressing those targets.

Recommended Story: How Do Front-End Loads Impact an Investment?

Receive News & Ratings for TapImmune Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TapImmune and related companies with MarketBeat.com's FREE daily email newsletter.